César A. Rodríguez

2.6k total citations
73 papers, 1.4k citations indexed

About

César A. Rodríguez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, César A. Rodríguez has authored 73 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in César A. Rodríguez's work include HER2/EGFR in Cancer Research (18 papers), Breast Cancer Treatment Studies (18 papers) and Cancer Treatment and Pharmacology (14 papers). César A. Rodríguez is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Breast Cancer Treatment Studies (18 papers) and Cancer Treatment and Pharmacology (14 papers). César A. Rodríguez collaborates with scholars based in Spain, United States and Canada. César A. Rodríguez's co-authors include Ian Reid, A. M. McHarg, Marion E. T. McMurdo, Miguel Martín, Juan Jesús Cruz, Eva Carrasco, Lourdes Calvo, Amparo Ruı́z, Carlos Jara and James B. Hendrickson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

César A. Rodríguez

71 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
César A. Rodríguez Spain 20 627 372 221 211 138 73 1.4k
Ewa Mrózek United States 20 756 1.2× 182 0.5× 217 1.0× 257 1.2× 74 0.5× 45 1.6k
Marco Venturini Italy 19 1.0k 1.6× 401 1.1× 213 1.0× 236 1.1× 39 0.3× 43 1.9k
Susan L. Woods Australia 18 509 0.8× 313 0.8× 520 2.4× 175 0.8× 55 0.4× 57 1.6k
Tanya E. Keenan United States 20 1.1k 1.8× 388 1.0× 425 1.9× 365 1.7× 59 0.4× 43 2.1k
Leslie G. Walker United Kingdom 17 663 1.1× 495 1.3× 104 0.5× 197 0.9× 229 1.7× 28 1.5k
Marisa C. Weiss United States 15 929 1.5× 403 1.1× 363 1.6× 316 1.5× 69 0.5× 31 1.9k
Judith Hurley United States 24 1.1k 1.7× 646 1.7× 219 1.0× 150 0.7× 65 0.5× 74 2.3k
Amy Mulick United Kingdom 21 262 0.4× 282 0.8× 202 0.9× 546 2.6× 153 1.1× 55 1.5k
Ying Pang China 24 440 0.7× 396 1.1× 444 2.0× 174 0.8× 93 0.7× 116 1.6k
Nicole McCarthy Australia 20 769 1.2× 330 0.9× 478 2.2× 246 1.2× 258 1.9× 76 1.7k

Countries citing papers authored by César A. Rodríguez

Since Specialization
Citations

This map shows the geographic impact of César A. Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by César A. Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites César A. Rodríguez more than expected).

Fields of papers citing papers by César A. Rodríguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by César A. Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by César A. Rodríguez. The network helps show where César A. Rodríguez may publish in the future.

Co-authorship network of co-authors of César A. Rodríguez

This figure shows the co-authorship network connecting the top 25 collaborators of César A. Rodríguez. A scholar is included among the top collaborators of César A. Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with César A. Rodríguez. César A. Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nooka, Ajay K., Jonathan L. Kaufman, César A. Rodríguez, et al.. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology. 204(6). 2227–2232.
2.
Rodríguez, César A., Mar Abad, José Antonio Moreno-Muñoz, et al.. (2024). PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer. Cancer Medicine. 13(17). e70101–e70101. 3 indexed citations
3.
Llombart‐Cussac, Antonio, Beatriz Rojas, Raquel Andrés, et al.. (2023). Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers. 15(5). 1529–1529. 2 indexed citations
4.
Ciruelos, Eva, Álvaro Montaño, César A. Rodríguez, et al.. (2020). Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). European Journal of Cancer Care. 29(4). e13253–e13253. 7 indexed citations
5.
Redondo, Andrés, Manuel Ramos Vázquez, Luís Manso, et al.. (2018). Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets and Therapy. Volume 11. 5845–5852. 5 indexed citations
6.
Templeton, Arnoud J., Álvaro Rodríguez-Lescure, A. Ruíz, et al.. (2018). Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology. 20(12). 1548–1556. 10 indexed citations
7.
8.
Peñas, R. de las, Ana Blasco, Javier de Castro, et al.. (2016). SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016). Clinical & Translational Oncology. 18(12). 1237–1242. 8 indexed citations
9.
Grávalos, Cristina, César A. Rodríguez, Adriano de Paula Sabino, et al.. (2016). SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clinical & Translational Oncology. 18(12). 1243–1253. 24 indexed citations
10.
Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38. 107 indexed citations
11.
Bellmunt, Joaquim, et al.. (2014). SEOM clinical guidelines for the treatment of renal cell carcinoma. Clinical & Translational Oncology. 16(12). 1043–1050. 32 indexed citations
12.
13.
Lü, Jing, Mingxin Wen, Yurong Huang, et al.. (2013). C2ORF40suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics. 8(6). 571–583. 40 indexed citations
14.
Liu, Yueyong, Shancheng Ren, Andrés Castellanos‐Martín, et al.. (2012). Multiple Novel Alternative Splicing Forms of FBXW7α Have a Translational Modulatory Function and Show Specific Alteration in Human Cancer. PLoS ONE. 7(11). e49453–e49453. 11 indexed citations
15.
Baró, Eva, J. Carulla, Javier Cassinello, et al.. (2010). Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Supportive Care in Cancer. 19(5). 657–666. 20 indexed citations
16.
Ciruelos, Eva, Javier Cortés, H. Cortés-Funes, et al.. (2009). Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Annals of Oncology. 21(7). 1442–1447. 10 indexed citations
17.
Díaz, Nieves, et al.. (2008). Patients’ perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. Clinical & Translational Oncology. 10(11). 753–757. 25 indexed citations
18.
Rodríguez, César A., et al.. (2007). Gastropexia profiláctica en perros por medio de endocirugia. Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona). 27(4). 270. 1 indexed citations
19.
García‐Estévez, Laura, Ignasi Tusquets, Montse Muñoz, et al.. (2007). Advanced breast cancer: chemotherapy phase III trials that change a standard. Anti-Cancer Drugs. 18(7). 843–859. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ewa Mrózek Breakdown of academic impact, for papers by Marco Venturini Breakdown of academic impact, for papers by Susan L. Woods Breakdown of academic impact, for papers by Tanya E. Keenan Breakdown of academic impact, for papers by Leslie G. Walker Breakdown of academic impact, for papers by Marisa C. Weiss Breakdown of academic impact, for papers by Judith Hurley Breakdown of academic impact, for papers by Amy Mulick Breakdown of academic impact, for papers by Ying Pang Breakdown of academic impact, for papers by Nicole McCarthy
Rankless by CCL
2026